United States

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

3:59pm EST
Change (% chg)

$-0.33 (-0.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Mon, Jan 9 2017

BRIEF-Agios provides early-stage data on AG-120 in glioma, chondrosarcoma patients

* Agios announces phase 1 data from dose expansion cohorts of AG-120 in patients with IDH1 mutant positive glioma and chondrosarcoma Source text for Eikon: Further company coverage:

BRIEF-Agios posts Q3 shr loss $1.63

* Agios Pharmaceuticals inc - now expects to end 2016 with more than $550 million of cash, cash equivalents and marketable securities

BRIEF-Agios Pharma says Celgene expects to submit NDA to U.S. FDA for enasidenib

* Celgene corporation expects to submit a new drug application to U.S. FDA for Enasidenib (ag-221)

BRIEF-Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer

* Glenn Goddard, senior vice president of finance, will be leaving company at end of September to pursue other opportunities

BRIEF-Agios Pharmaceuticals reports qtrly loss per share $1.47

* Collaboration revenue was $7.0 million for quarter ended June 30, 2016, compared to $13.2 million for comparable period in 2015

Select another date: